239,668 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets bought a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 239,668 shares of the company's stock, valued at approximately $987,000. BNP Paribas Financial Markets owned about 0.14% of Relay Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of RLAY. Steward Partners Investment Advisory LLC raised its position in Relay Therapeutics by 160.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 6,500 shares of the company's stock valued at $27,000 after purchasing an additional 4,000 shares during the last quarter. Stifel Financial Corp purchased a new stake in shares of Relay Therapeutics in the 4th quarter worth approximately $42,000. Cibc World Markets Corp purchased a new stake in shares of Relay Therapeutics in the 4th quarter worth approximately $47,000. Summit Investment Advisors Inc. grew its stake in shares of Relay Therapeutics by 41.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 12,730 shares of the company's stock worth $52,000 after buying an additional 3,760 shares during the last quarter. Finally, Virtus ETF Advisers LLC boosted its stake in Relay Therapeutics by 26.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 14,873 shares of the company's stock valued at $61,000 after purchasing an additional 3,092 shares during the last quarter. Institutional investors own 96.98% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wells Fargo & Company began coverage on Relay Therapeutics in a report on Thursday, April 17th. They issued an "equal weight" rating and a $4.00 target price on the stock. The Goldman Sachs Group dropped their price target on Relay Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. Guggenheim dropped their price target on Relay Therapeutics from $30.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Stifel Nicolaus decreased their price objective on shares of Relay Therapeutics from $27.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Relay Therapeutics in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.67.

Insider Transactions at Relay Therapeutics

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 12,943 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $3.00, for a total value of $38,829.00. Following the sale, the chief financial officer now directly owns 355,376 shares of the company's stock, valued at approximately $1,066,128. This represents a 3.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sanjiv Patel sold 61,422 shares of the company's stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $2.97, for a total transaction of $182,423.34. Following the completion of the sale, the chief executive officer now directly owns 821,667 shares in the company, valued at approximately $2,440,350.99. The trade was a 6.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 94,320 shares of company stock valued at $280,981. Corporate insiders own 4.87% of the company's stock.

Relay Therapeutics Stock Performance

NASDAQ:RLAY traded up $0.06 during trading hours on Monday, reaching $2.91. The company's stock had a trading volume of 939,082 shares, compared to its average volume of 2,078,045. The company has a market capitalization of $498.90 million, a P/E ratio of -1.11 and a beta of 1.65. Relay Therapeutics, Inc. has a 12 month low of $1.78 and a 12 month high of $10.72. The stock has a 50 day moving average price of $2.80 and a two-hundred day moving average price of $3.80.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.04. The business had revenue of $7.68 million for the quarter, compared to analyst estimates of $0.01 million. The business's revenue for the quarter was down 23.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.62) earnings per share. As a group, analysts predict that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.